PROMIS – PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score

Publication Name: Cancer Research

Author(s): Hatem Soliman, Sarah Untch, Lisette Stork-Sloots

PROMIS is a prospective study that will investigate the additional value of MammaPrint, BluePrint and TargetPrint in women with an intermediate Oncotype DX score. An initial CRF – capturing baseline patient characteristics, pathology information, Oncotype DX score and the recommended … Continued

MINT I – Multi-Institutional Neoadjuvant Therapy, MammaPrint Project I

Publication Name: Cancer Research

Author(s): Charles Cox, Peter Blumencranz, Douglas Reintgen, Ruben Saez, Nicole Howard, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück

Treatment of locally advanced breast cancer (LABC) with neoadjuvant chemotherapy measures the in vivo response to chemotherapy,1 assesses long-term clinical outcomes associated with that response2,3 and enables some patients to undergo breast-conservation therapy due to therapeutic down-staging of the tumor.  In the current study, the … Continued

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer

Publication Name: Cancer Research

Author(s): C.A. Drukker, M.V. Nijenhuis, S.G.Elias, J. Wesseling, N.S. Russell, P. Whitworth, R. Patel, F. de Snoo, L.J. van’t Veer, P.D. Beitsch, E.J.Th. Rutgers

The 70-­‐gene signature is able to predict the risk of locoregional recurrence. We observed a significantly lower incidence of locoregional recurrence in patients with a low risk 70-­‐gene signature result compared to those with high risk 70-­‐gene signature result, independent … Continued

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer

Publication Name: Cancer

Author(s): Mo Yang, MS; Suja Rajan, PhD; and Amalia M. Issa, PhD, MPH

BACKGROUND: Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph nodenegative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the … Continued

Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial

Publication Name: SABCS 2012 Poster

Author(s): Giuseppe Viale, Leen Slaets, Femke de Snoo, Laura J. van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Jeroen van den Akker, Lisette Stork-Sloots, Kristel Engelen, Leila Russo, Patrizia Dell’Orto, Fatima Cardoso

Biology has become the main driver of breast cancer therapy. Intrinsic biological subtypes by gene expression profiling have been identified.  Pathology can be used to define surrogates of these subtypes but these are not always concordant, which may lead to … Continued

Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine

Publication Name: Press Release

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 20, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that it has been granted the International Organization for Standardization (ISO) 13485 certification for all activities … Continued

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

Publication Name: Annals of Surgical Oncology

Author(s): Bichlien Nguyen, Pino G. Cusumano, Kenneth Deck, Deborah Kerlin, Agustin A. Garcia, Julie L. Barone, Edgardo Rivera, Katharine Yao, Femke A. de Snoo, Jeroen van den Akker, Lisette Stork-Sloots, Daniele Generali

Purpose: To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Methods: BluePrint, MammaPrint, and TargetPrint were all performed on … Continued